InSilicoTrials

A responsible use of #AI is crucial in many #clinical applications To this end, using transparent and explainable #AImethods can enhance our understanding of why an #AImodel behaves the way it does, and allow us to confidently deploy the model in sensitive settings. Our Head of AI Marco Virgolin, PhD was recently invited at ASML Research - Diagnostic & Data Science Group to give a seminar about #SymbolicRegression, a technique to learn interpretable models from #data, in the form of #equations. Symbolic regression is an important technique also for InSilicoTrials, as it enables to advance our understanding of #pharmacokinetics #pharmacodynamics and interpretable #patient survival analysis.

𝐈𝐧𝐒𝐢𝐥𝐢𝐜𝐨𝐓𝐫𝐢𝐚𝐥𝐬 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐇𝐒𝐁𝐂 𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝟏𝐇 𝟐𝟎𝟐𝟒 The HSBC Healthcare Annual Report 1H 2024 provides a comprehensive analysis of the #healthcare sector, covering trends in #venturecapital investments, #biopharma, medical devices, and #healthtech.   Notably, 𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 is included between the most prominent companies within the 𝗜𝗻𝘀𝗶𝗴𝗵𝘁 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗮𝗻𝗱 𝗜𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 (𝗜𝗣𝗜) sub-sector, on slide 34. In such slide, we can see the most important companies in the #computationalbiology landscape in 1H 2024 for USA and Europe broken down into 4 sectors: ✅ #AI Discovery (AID) ✅ #Diagnostics (Dx) ✅ #Clinical Response Predication (CRP) ✅ Insight #Platform & #Infrastructure (IPI).   We are honoured by this mention, as it highlights our work in democratizing #modelingandsimulation, making these advanced tools more accessible to #researchers and organizations worldwide.   Authored by HSBC Innovation Banking's division, the report serves as a valuable resource for #stakeholders looking to understand the current and future directions of the healthcare industry. 🔗 Download full report: https://lnkd.in/ggqMVkCH

𝗣𝘂𝗯𝗹𝗶𝗰 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗼𝗻 𝗔𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗜𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲 𝗶𝗻 𝗗𝗿𝘂𝗴 & 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 🗓️ August 6, 2024 | 10:00 AM - 5:30 PM EDT 📍 FDA Great Room, 10903 New Hampshire Ave., Silver Spring, MD, 20993 (also available virtually via Zoom)   Thrilled to announce that our CEO Luca Emili will be speaking at this significant event, organized by the FDA and the Clinical Trials Transformation Initiative (CTTI). The workshop aims to bring together #drugdevelopers, #AI experts, and #regulatory professionals to discuss the guiding principles for the responsible application of AI in developing safe and effective #drugs and biological products.   Luca will share his insights on the challenges of trustworthy and responsible AI use in #drugdevelopment, alongside other #industry experts.   Participants will engage in presentations and panel discussions on the following key topics: 🔸 𝗠𝗼𝗱𝗲𝗹 𝗗𝗲𝘀𝗶𝗴𝗻: Integrating multidisciplinary expertise. 🔸 𝗗𝗮𝘁𝗮 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀: Access, quality, and #syntheticdata. 🔸 𝗕𝗮𝗹𝗮𝗻𝗰𝗶𝗻𝗴 𝗔𝗜 𝗠𝗼𝗱𝗲𝗹𝘀: Performance, explainability, and transparency. 🔸 𝗛𝘂𝗺𝗮𝗻 𝗶𝗻 𝘁𝗵𝗲 𝗟𝗼𝗼𝗽: Strategies for #human integration in AI decisions.   ✍ Register Now: https://lnkd.in/dv5XZ9qW

𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝗵𝗲𝗮𝗱𝘀 𝘁𝗼 𝟰𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗺𝗥𝗡𝗔-𝗕𝗮𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 📍 29-31 July | Boston   𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 will participate in the world's largest gathering for #mRNA professionals, bringing together over 350 experts and enthusiasts to explore the latest #scientific and strategic insights in #mRNAtherapeutics.    Our colleagues Sofia Stathopoulos and Fianne Sips will represent us at the event, showcasing our innovative solutions:   🔹 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗼𝗿 Our Clinical Trial Simulator streamlines and de-risks RNA #therapeutic trials, optimizing designs from Phase I-IV using real-world and #syntheticdata to maximize success probabilities and assess risk-reward scenarios. 🔹 𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗩𝗔𝗖𝗖𝗜𝗡𝗘 𝗦𝘂𝗶𝘁𝗲 The InSilico Vaccine Suite enhances trial design and outcomes analysis, leveraging advanced models to predict #vaccine effects, optimize dosing schedules, and support #regulatory submissions with comprehensive data insights. 🔹 𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝗳𝗼𝗿 𝗥𝗡𝗔 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 Our platform for RNA therapies accelerates and optimizes #clinicaltrials, predicting key #biomarkers and outcomes, extrapolating non-clinical data to human response, and designing efficient trials to bring new #therapies to market faster.   👉 Get in touch to find more on how our #insilico approaches can optimize trials’ design & streamline #drugdevelopment: https://lnkd.in/dwKkjkVi

𝗘𝗗𝗜𝗧𝗛-𝗖𝗦𝗔 𝗙𝗶𝗻𝗮𝗹 𝗘𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝗠𝗲𝗲𝘁𝗶𝗻𝗴: 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗛𝘂𝗺𝗮𝗻 𝗧𝘄𝗶𝗻 🧬 🗓 15 & 16 July 2024 | KIT Royal Tropical Institute, Amsterdam This second and final EDITH-CSA ecosystem meeting aims to update the #VirtualHumanTwin (#VHT) roadmap progress, gather input on remaining elements, and begin ecosystem #validation for final recommendations, concluding the consortium's collaborative efforts.   As member of 𝗘𝗗𝗜𝗧𝗛'𝘀 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗔𝗱𝘃𝗶𝘀𝗼𝗿𝘆 𝗕𝗼𝗮𝗿𝗱(https://lnkd.in/dihcuYMJ), InSilicoTrials is present at this event, with our colleagues Alessia Baretta, Vincenzo Carbone, PhD, and Marco Virgolin, PhD joining breakout discussions to provide input for the upcoming final roadmap. The involvement and engagement of #industrial #stakeholders in the #VHT ecosystem are vital to ensure the success of such a flagship initiative.   🔗 https://lnkd.in/dJEbap4U #digitaltwin #insilico #modelingandsimulation #computationalmodeling #insilicomedicine #virtualpatient

The In Silico World (ISW) project - which InSilicoTrials is part of - aims to lower the barriers to adopting #insilico methodologies in developing and derisking new #medicalproducts, including #regulatory evaluation. In 2021, at its outset, the ISW consortium compiled a 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵-𝗪𝗲𝗮𝗸𝗻𝗲𝘀𝘀𝗲𝘀-𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀-𝗧𝗵𝗿𝗲𝗮𝘁𝘀 (𝗦𝗪𝗢𝗧) 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 that is summarised here: https://lnkd.in/d36-wTZe. As the ISW project concludes in December 2024, the consortium seeks to engage the ISW Community of Practice on Slack to update the original #SWOT analysis. This effort aims to equip the community with strong, factual arguments to advocate for #insilicotrials to senior management across the sector. 🙌 We invite all members, particularly those in #industry or #governmental roles, to participate in this important discussion: https://lnkd.in/ddVA8R-W

𝐄𝐦𝐩𝐨𝐰𝐞𝐫𝐢𝐧𝐠 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐀𝐈: 𝐁𝐑𝐀𝐈𝐍𝐓𝐄𝐀𝐒𝐄𝐑 𝐚𝐭 𝐭𝐡𝐞 𝐅𝐨𝐫𝐞𝐟𝐫𝐨𝐧𝐭 𝐨𝐟 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 The BRAINTEASER Project - which InSilicoTrials is part of - is revolutionizing healthcare for #ALS and #MS patients by leveraging advanced #AI models to analyze diverse data sources. Key components include the #PatientApp, which provides #personalizedhealth insights, and the #ClinicalDashboard, which aids #healthcare professionals in tracking #diseaseprogression and tailoring #treatments. Progress: ✅ Over 250 patients enrolled, aiming for 300. ✅ Positive preliminary feedback from both #patients and #clinicians.

🌟 InSilicoTrials in the Spotlight! 🌟 We are excited to share that InSilicoTrials was recently featured on TV! The Rai - Radiotelevisione Italiana program highlighted our journey from a startup to winning the AI Startup of the Year award in Silicon Valley this past April, showcasing our innovative use of #AI in accelerating the development of new #drugs. 🇮🇹 https://lnkd.in/dNhyWp4X Andrea Saule

𝗕𝗼𝗼𝘀𝘁𝗶𝗻𝗴 𝗗𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗶𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 𝗔 𝗡𝗲𝘄 𝗙𝗗𝗔 𝗗𝗿𝗮𝗳𝘁 𝗚𝘂𝗶𝗱𝗮𝗻𝗰𝗲 The FDA has issued draft guidance recommending that sponsors create comprehensive #diversity action plans for #clinicalstudies. This initiative -𝘋𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘈𝘤𝘵𝘪𝘰𝘯 𝘗𝘭𝘢𝘯𝘴 𝘵𝘰 𝘐𝘮𝘱𝘳𝘰𝘷𝘦 𝘌𝘯𝘳𝘰𝘭𝘭𝘮𝘦𝘯𝘵 𝘰𝘧 𝘗𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘯𝘵𝘴 𝘧𝘳𝘰𝘮 𝘜𝘯𝘥𝘦𝘳𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘦𝘥 𝘗𝘰𝘱𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘚𝘵𝘶𝘥𝘪𝘦𝘴 𝘎𝘶𝘪𝘥𝘢𝘯𝘤𝘦 𝘧𝘰𝘳 𝘐𝘯𝘥𝘶𝘴𝘵𝘳𝘺 - aims to improve the inclusion of underrepresented populations, ensuring #medicaltreatments and devices are safe, effective, and accessible for everyone. 𝗪𝗵𝘆 𝗶𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: 🔸 Wider Representation: Diverse participation helps reveal how treatments work across different ages, sexes, races, and ethnicities, enhancing overall efficacy. 🔸 Health Equity: Addressing historical underrepresentation ensures advancements benefit all communities, promoting #fairhealthcare. At InSilicoTrials, we're dedicated to supporting these efforts with advanced #insilico methods, ensuring robust and inclusive #trialdesigns that meet #regulatory standards and promote #healthequity. 👉 Read the full guidance: https://lnkd.in/dAn6tTRi

Save the Date: 17th Symposium on Pharmacokinetics and Drug Metabolism 📅November 12 - 13 | AstraZeneca site in Mölndal We are thrilled to announce that InSilicoTrials is a gold sponsor for the upcoming 17th Symposium on Pharmacokinetics and Drug Metabolism. The event will highlight key advancements in #biotransformation, #drug transporters, pharmacokinetics/pharmacodynamics in #rarediseases, bridging strategies for drug-device products, and drug combination therapies. 👇